1. Home
  2. MLYS vs AMPS Comparison

MLYS vs AMPS Comparison

Compare MLYS & AMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • AMPS
  • Stock Information
  • Founded
  • MLYS 2019
  • AMPS 2009
  • Country
  • MLYS United States
  • AMPS United States
  • Employees
  • MLYS N/A
  • AMPS N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • AMPS Electric Utilities: Central
  • Sector
  • MLYS Health Care
  • AMPS Utilities
  • Exchange
  • MLYS Nasdaq
  • AMPS Nasdaq
  • Market Cap
  • MLYS 526.1M
  • AMPS 608.0M
  • IPO Year
  • MLYS 2023
  • AMPS N/A
  • Fundamental
  • Price
  • MLYS $10.86
  • AMPS $3.96
  • Analyst Decision
  • MLYS Strong Buy
  • AMPS Strong Buy
  • Analyst Count
  • MLYS 2
  • AMPS 9
  • Target Price
  • MLYS $30.00
  • AMPS $5.38
  • AVG Volume (30 Days)
  • MLYS 263.5K
  • AMPS 1.1M
  • Earning Date
  • MLYS 03-20-2025
  • AMPS 03-13-2025
  • Dividend Yield
  • MLYS N/A
  • AMPS N/A
  • EPS Growth
  • MLYS N/A
  • AMPS N/A
  • EPS
  • MLYS N/A
  • AMPS 0.22
  • Revenue
  • MLYS N/A
  • AMPS $185,992,000.00
  • Revenue This Year
  • MLYS N/A
  • AMPS $30.74
  • Revenue Next Year
  • MLYS N/A
  • AMPS $17.00
  • P/E Ratio
  • MLYS N/A
  • AMPS $17.86
  • Revenue Growth
  • MLYS N/A
  • AMPS 25.90
  • 52 Week Low
  • MLYS $8.58
  • AMPS $2.71
  • 52 Week High
  • MLYS $16.91
  • AMPS $7.28
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 51.57
  • AMPS 51.87
  • Support Level
  • MLYS $9.81
  • AMPS $3.80
  • Resistance Level
  • MLYS $10.79
  • AMPS $4.14
  • Average True Range (ATR)
  • MLYS 0.62
  • AMPS 0.23
  • MACD
  • MLYS 0.15
  • AMPS 0.02
  • Stochastic Oscillator
  • MLYS 100.00
  • AMPS 78.82

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About AMPS Altus Power Inc.

Altus Power Inc is a developer, owner, and operator of large-scale photovoltaic and energy storage systems across the United States. The company serve commercial, industrial, public sector, and community solar customers. Its mission is to drive the clean energy transition by developing and operating solar generation and energy storage facilities. It owns a diverse portfolio of solar PV systems and has long-term agreements with enterprise entities and residential customers. Their primary product offerings include leases and revenue contracts for solar power generation, alongside electric vehicle charging and energy storage solutions. Revenue streams include power purchase agreements, net metering credit agreements, and SREC revenue.

Share on Social Networks: